View the results › Events › Játssz – Vitázz: Gyógyszered az életed - az árva gyógyszerek sorsa Magyarországon / Life essentials - What's up with orphan drugs - the Hungarian scenario

Játssz – Vitázz: Gyógyszered az életed - az árva gyógyszerek sorsa Magyarországon / Life essentials - What's up with orphan drugs - the Hungarian scenario

Total results in % based on votes of 5 people

Policy

1

Since resources are limited, there should be a limit and only cost effective drugs that benefit the greater number of patients should be reimbursed. If a drug purchaser has to choose between treating 10 patients with drug A or 1 with drug B for a rare disease, then the choice should always be to treat 10 with drug A.

2

Only cost effective drugs should be reimbursed, but the approach for orphan drugs should be different than for common diseases. If there is any doubt about the cost effectiveness of an orphan drug, it should be exceptionally reimbursed in certain cases.

3

Like position 2, but if there is any doubt about the cost effectiveness of an orphan drug, the benefit of doubt should be given to the patient and the drug should be reimbursed systematically.

4

Health is a priority for European citizens. Just as efforts to rescue people after an accident are not restricted, efforts to rescue a patient with a rare disease should not be limited. Cost effectiveness should not be the parameter on which to base reimbursement decisions.

Overview of the new policies developed by players in this event.

According to a published working document, Szell Kalman Plan proposes a European level risk management concerning Orphan drugs. Whatever the details of this recommendation, parallel to market authorisation, the factors directing patients' access to these drugs could also be tackled at a wider than regional or national levels. This would mean different things for different actors, for example, it may bring about a stricter Eu level control over member state budgetary issues, still Eu level solidarity would bring hope to many.

A Széll Kálmán Terv intézkedés tervezetei közt szerepel az árva gyógyszerek esetében EU-s szintű kockázatvállalás. Bármi is legyen e javaslat pontos tartalma, a gyógyszerek fejlesztését, forgalomba hozatalát szabályozó kérdésekhez hasonlóan európai szintűvé lehetne tenni a hozzáférést meghatározó tényezőket is. Jelentse ez akár a nemzeti költségvetések szorosabb EU-s szintű kontrollját, a társadalombiztosítási kérdések európai szintű szoldiratásba emelése sokaknak adna reményt.